[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Khyber Teaching Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":435},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,40,74,102,132,158,180,203,230,254,277,311,335,359,384,405],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100644713","early-phase-1-comparison-of-topical-clascoterone-and-adapalene-for-mild-acne-vulgaris-100644713",false,"NCT07673094","Comparison of Topical Clascoterone and Adapalene for Mild Acne Vulgaris","Comparison of Efficacy of Topical Clascoterone With Topical Adapalene in the Treatment of Mild Acne Vulgaris","Inclusion Criteria:\n\n* Clinical diagnosis of mild acne vulgaris as per operational definition\n* Male or female patients\n* Age 12 to 35 years\n\nExclusion Criteria:\n\n* History of acne conglobata\n* History of acne fulminans\n* Use of topical anti-acne medications within the last 4 weeks\n* Use of systemic anti-acne therapy within the last 12 weeks\n* Known hypersensitivity or allergy to clascoterone or adapalene\n* History of eczema\n* History of rosacea\n* History of seborrheic dermatitis\n* History of psoriasis\n* Presence of active skin infections\n* Pregnant women\n* Lactating women","ALL","12 Years","35 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"EARLY_PHASE1","There is no local data available regarding the comparative efficacy of topical clascoterone and topical adapalene, particularly in patients with mild acne vulgaris. The findings of this study will help dermatologists identify the more effective topical treatment for mild acne vulgaris, leading to improved patient outcomes and better utilization of healthcare resources. Furthermore, the study will contribute local data to the existing literature and may assist in developing evidence-based treatment recommendations for patients with mild acne vulgaris in our setting.\n\nPatients meeting the inclusion criteria from the Dermatology Unit, Khyber Teaching Hospital, MTI, Peshawar will be incorporated into the study following approval from the ethics committee. At the commencement of the trial, baseline demographics including gender, age, height, weight, BMI, duration of acne, socioeconomic status, profession, monthly income, education level and residential status will be documented. An elaborate explanation of the process involved in the study will be provided to the participants, and consent will be taken following an explanation of the pros and cons involved.\n\nRandomization will be performed by computer generated random list. The group assignments will be put into sealed envelopes, which will be opened when the patient will be included in study. 30 patients will be in topical clascoterone group (A) while 30 patients will be in topical adapalene group (B).\n\nPatients allocated to Group A will receive topical clascoterone 1% cream. It is required that they will clean their faces using a mild cleansing agent, dry their faces and thereafter apply a thin coating of clascoterone 1% cream to their whole face area in the morning and evening for 12 consecutive weeks.\n\nPatients allocated to Group B will receive topical adapalene 0.1% gel. Patients will cleanse the skin using a gentle cleanser, allow it to dry in the air for 10 minutes, and then apply one pea-sized amount of 0.1% adapalene gel over their entire affected area of the face once a day before going to bed for 12 weeks.",[27],"Acne Vulgaris","NOT_YET_RECRUITING","2026-06-24",{"date":31,"type":32},"2026-06-29","ACTUAL",{"date":34,"type":21},"2026-08-15",{"date":36,"type":21},"2027-08-22",{"name":38,"class":39},"Khyber Teaching Hospital","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":49,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100599933","phase-4-effectiveness-of-per-operative-bupivicaine-in-reducing-postoperative-pain-at-port-site-and-improving-mobility-in-knee-arthoscopic-procedures-100599933","NCT07090928","Effectiveness of Per-Operative Bupivicaine in Reducing Postoperative Pain at Port Site and Improving Mobility in Knee Arthoscopic Procedures","Inclusion Criteria Either Male or Female Age range: 18-70 Years Patients scheduled to undergo elective knee arthroscopic procedures Able to understand the VAS pain scale Exclusion Criteria Either Male or Female Age range: 18-70 Years Patients scheduled to undergo elective knee arthroscopic procedures Able to understand the VAS pain scale Known hypersensitivity or allergy to bupivacaine or any local anesthetics Chronic pain conditions requiring regular pain medications History of drug abuse (mainly to opioids) Pregnant women Pre-existing impaired knee mobility No willing to participate in trial","18 Years","70 Years",{"count":20,"type":21},[50],"PHASE4","The investigator's aim is to evaluate the effectiveness of per-operative bupivacaine infiltration at arthroscopic port sites in reducing post-operative pain compared to placebo in patients undergoing knee arthroscopic procedures.",[53],"Arthroscopic Surgery",[55,56,57,58,59,60,61,62,63],"Bupivacaine","Postoperative Pain","Port Site Pain","Arthroscopy","Mobility Improvement","Local Anesthetic","Perioperative Analgesia","Minimally Invasive Surgery","Randomized Controlled Trial","RECRUITING","2026-06-20",{"date":67,"type":32},"2026-06-25",{"date":69,"type":32},"2026-03-10",{"date":71,"type":21},"2026-06",{"name":38,"class":39},1,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":73},"100642506","early-phase-1-3-vs-5-days-of-amoxicillin-for-childhood-pneumonia-an-rct-100642506","NCT07647835","3 vs. 5 Days of Amoxicillin for Childhood Pneumonia: An RCT","Comparison 0f 03days Vs 05days Amoxicillin In Uncomplicated Community Acquired Pneumonia In Children. A Randomized Controlled Trial","Pnemonia","Inclusion criteria:\n\n* Age; ≥ 3 months to 5 years\n* Fever; recorded temperature of ≥100.4 f or guardian reported fever within 2 days\n* Cough; observed or reported within 3 days\n* Tachypnea;\n* 3 months to 1 years ≥ 50 breaths per minute\n* 1 years to 5 years ≥ 40 breaths per minute\n* C- reactive protein ≥ 40\n* White blood cells ≥ 12200\n* Chest X-ray;\n* Presence of a dense opacity occupying a portion or whole of lobe with or without air Broncho grams.\n\nExclusion criteria:\n\n* Patient who is Lethargic and unable to tolerate orally.\n* Capillary refill greater than 2 second\n* Chronic lung disease\n* Congenital heart disease or sickle cell anemia patient\n* Immunocompromised patient\n* malnourished\n* Known or suspected tuberculosis patient\n* Patient has used prior antibiotic within 2 days\n* Allergic to penicillin or amoxicillin\n* C-reactive protein greater than 72\n* White blood cells greater than 25000\n* Chest x rays show linear or patchy or peri bronchial opacity\n* Presence of pleural effusions\n* Empyema, lung abscess, necrotizing pneumonia or pneumatocele\n* Other alternative diagnosis like wheezing syndrome (Bilateral wheezing on auscultation)","3 Months","5 Years",{"count":85,"type":21},250,[24],"Pneumonia is the most common infection in children and leading to most common cause of mortality and morbidity in in children globally. Bacterial cause is mostly streptococcus pneumonia in children of 3 months to 5 years of age. Traditionally 7-10 antibiotic is used for uncomplicated community acquired pneumonia. World health organization (WHO) recommends 5 days of antibiotic for non-severe pneumonia with oral amoxicillin while National institute for health and care excellence (NICE) guidelines 2025 recommends 3-days course of amoxicillin in uncomplicated community acquired pneumonia.1,2 Most studies show Short course antibiotic is as effective as long course of antibiotic with fewer side effect. The Khyber Pakhtunkhwa province faces particular challenges due to limited healthcare access, malnutrition, and suboptimal vaccination coverage which leads to major burden of pneumonia in less than 5 years' children.7 There is need of local data about effectiveness of short course antibiotic in uncomplicated community acquired pneumonia. 3-day oral amoxicillin has better compliance and less side effect of medicine. Short course of oral amoxicillin is cost effective as pneumonia is more common in low socioeconomic population and 3-day course antibiotic is more economical and has better compliance. Long course of antibiotic leads to antibiotic resistance and adverse effects like diarrhea and other gastrointestinal symptoms.",[89,90],"Community Acquired Pneumonia","Childhood Pneumonia",[92,93],"Amoxcillin in childhood pneumonia","community acquired pneumonia","2026-06-09",{"date":96,"type":32},"2026-06-15",{"date":98,"type":21},"2026-06-01",{"date":100,"type":21},"2027-06-01",{"name":38,"class":39},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":109,"minAge":46,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100640535","balloon-tamponade-versus-gauze-packing-for-postpartum-hemorrhage-100640535","NCT07609589","Balloon Tamponade Versus Gauze Packing for Postpartum Hemorrhage","Comparison of Efficacy of Uterine Balloon Tamponade Versus Uterine Gauze Packing in Patients With Postpartum Hemorrhage With Uterine Atony","Inclusion Criteria:\n\n* Women aged 18 to 40 years\n* Gestational age between 37 and 42 weeks\n* Parity up to 4\n* Diagnosed with postpartum hemorrhage due to uterine atony\n\nExclusion Criteria:\n\n* Postpartum hemorrhage due to perineal, cervical, or vaginal trauma\n* Retained products of conception\n* Vaginal delivery after previous cesarean section\n* Known coagulation disorders\n* Sepsis","FEMALE","40 Years",{"count":112,"type":21},216,[114],"NA","Postpartum hemorrhage due to uterine atony is a major cause of maternal morbidity and mortality. This randomized controlled trial aims to compare the efficacy of uterine balloon tamponade and uterine gauze packing in controlling bleeding in women with postpartum hemorrhage. A total of 216 participants will be randomly assigned to one of the two treatment groups. All patients will receive standard medical management including uterotonic agents prior to intervention. The primary outcome is cessation of uterine bleeding within 24 hours after the procedure. This study aims to identify a safe and effective method for managing postpartum hemorrhage in a resource-limited setting.",[117,118],"Postpartum Hemorrhage","Uterine Atony",[120,121,122,123],"postpartum hemorrhage","uterine atony","balloon tamponade","uterine packing","2026-05-21",{"date":126,"type":32},"2026-05-27",{"date":128,"type":21},"2026-07-01",{"date":130,"type":21},"2027-01-10",{"name":38,"class":39},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":73},"100594201","phase-4-comparison-of-efficacy-of-topical-adaplene-gel-versus-crythotherapy-in-recurrent-plantar-warts-100594201","NCT07016360","Comparison of Efficacy of Topical Adaplene Gel Versus Crythotherapy in Recurrent Plantar Warts","Comparison of Efficacy of Topical Adapalene Gel Versus Cryotherapy in Recurrent Plantar Warts","Inclusion Criteria:\n\n\\-\n\nPatients age limit 18-60 Years Patients with either gender (Male\u002FFemale) Patients with recurrent plantar warts\n\nExclusion Criteria:\n\n* Pregnancy\u002Flactation. Pt on topical or systemic therapy in last 6 months. On immunosuppressants. \\> 5 lesions. Pts with local secondary infections.","60 Years",{"count":141,"type":21},98,[50],"This is a comparative study between two treatment options for skin viral infection.",[145],"Viral Warts",[147,148,149],"Plantar warts","Topical adapalene gel","Cryotherapy","2026-04-23",{"date":152,"type":32},"2026-04-29",{"date":154,"type":32},"2025-09-15",{"date":156,"type":21},"2026-09-15",{"name":38,"class":39},{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":109,"minAge":165,"maxAge":110,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":73},"100627187","role-of-the-who-labour-care-guide-in-improving-maternal-and-fetal-outcomes-100627187","NCT07445373","Role of the WHO Labour Care Guide in Improving Maternal and Fetal Outcomes","Role of WHO Labour Care Guide in Improving Maternal and Fetal Outcomes in Primi and Multigravida in Labour","Inclusion Criteria:\n\n* patient aged 20 to 40 years .\n* gestational age 37 to 42 weeks as per LMP.\n* parity UpTo 4\n* singketon pregnancy on ultrasound\n* patient presenating In labor as per operational definitons\n\nExclusion Criteria:\n\n* patients with breech presenation\n* pregnant women in whom trial of labor given outside the hospital,\n* women with complications like gestational diabetes,antepartum hemorrhage,severe preeclampsia\u002Feclampsia and medical disorders complicating the pregnancy\n* premature rupture of membranes","20 Years",{"count":167,"type":21},114,[114],"The goal of this randomized controlled trial is to compare the effectiveness of WHO labour care guide (LCG) with the WHO modified partogragh in improving the maternal and fetal outcomes among primigravida and multigravida in active labour .the study evaluates whether use of the Labour care guide leads to improved labour monitoring ,timely clinical decision making and better maternal and neonatal outcomes .this study will answer either of the two questions that is\n\n* There is no difference in maternal and fetal outcomes between women monitored with Wo labour care guide (LCG) and those monitored with the Modified Partogragh\n* There is a difference in maternal and fetal outcomes between women monitored with the WHO Labour care guide (LCG) and those monitored the modified Partogragh .",[171],"Labor and Delivery","2026-02-25",{"date":174,"type":32},"2026-03-03",{"date":176,"type":21},"2026-12",{"date":178,"type":21},"2027-06",{"name":38,"class":39},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":187,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":191,"conditions":192,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":73},"100604359","antireflux-suture-in-one-anastomsis-gastric-bypass-100604359","NCT07148492","Antireflux Suture In One Anastomsis Gastric Bypass","Antireflux Suture In Laparoscopic One Anastomsis Gastric Bypass Surgery, A Randomised Control Trial","Inclusion Criteria:\n\n* Patients undergoing one anastomosis gastric bypass surgery\n\nExclusion Criteria:\n\n* Non consenting individuals",true,{"count":189,"type":21},316,[114],"To prevent refulx symptoms in a type of bariatric surgery, a suture is taken.there is no enough evidence in support of or against the suture. our study aims to compare the symptoms of patients in whom the suture is taken and in those in whom it is not.",[193,194],"Reflux Disease, Gastro-Esophageal","Vomiting, Postoperative","2025-08-28",{"date":197,"type":32},"2025-08-29",{"date":199,"type":32},"2024-01-01",{"date":201,"type":21},"2025-09-30",{"name":38,"class":39},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":210,"maxAge":139,"enrollmentInfo":211,"targetDuration":4,"studyType":22,"phases":213,"briefSummary":214,"conditions":215,"keywords":218,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":225,"completionDateStruct":227,"leadSponsor":229,"locationsCount":73},"100592326","phase-4-comparison-of-needling-and-microneedling-plus-phototherapy-in-localized-vitiligo-patients-100592326","NCT06991972","Comparison of Needling and Microneedling Plus Phototherapy in Localized Vitiligo Patients","Puncture to Repigment: A Comparative Analysis Of Needling vs. Microneedling Along With NBUVB in Treatment of Non-Segmental Vitiligo","Inclusion Criteria:\n\n* Both male and female\n* Age 15-60 years\n* Patients having vitiligo for more than 1 year\n\nExclusion Criteria:\n\n* Patients with tendency of keloid formation or hypertrophic scarring\n* Patients with any bleeding disorder, coagulation defect or using anti platelets\n* Any local infection at the treatment site\n* Patients who had received systemic therapy in last 6 months","15 Years",{"count":212,"type":21},80,[50],"This randomized controlled trial aims to compare the efficacy of needling versus microneedling, both followed by narrowband UVB therapy, in achieving repigmentation in patients with localized stable non-segmental vitiligo.",[216,217],"Vitiligo","Non-segmental Vitiligo",[219,220,221],"vitiligo","needling","microneedling","2025-08-25",{"date":224,"type":32},"2025-09-02",{"date":226,"type":32},"2025-03-01",{"date":228,"type":21},"2025-08-31",{"name":38,"class":39},{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":73},"100603003","early-vs-late-laparoscopic-cholecystectomy-after-common-bile-duct-stones-clearance-through-ercp-100603003","NCT07130864","Early vs Late Laparoscopic Cholecystectomy After Common Bile Duct Stones Clearance Through Ercp.","Early Vs Late Laparoscopic Cholecystectomy After Ercp For Choledocholithiasis, A Randomised Control Trial.","Inclusion criteria :\n\n.All patients undergoing laparoscopic cholecystectomy who had concomitant choledocholithiasis for which ercp is done.\n\nexclusion criteria:\n\n.Non consenting indviduals",{"count":238,"type":21},136,[114],"There is controversy about timing of cholecystectomy after the common bile duct is cleared of stones. our study aims to compare the results of early vs late cholecystectomy.",[242,243,244,245],"Laparoscopic Cholecystectomy","Choledocholithiasis","ERCP","Bile Duct Injury","2025-08-18",{"date":248,"type":32},"2025-08-19",{"date":250,"type":32},"2025-05-23",{"date":252,"type":21},"2025-12-31",{"name":38,"class":39},{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":73},"100602571","outcomes-of-a-single-chest-drain-vs-two-drains-100602571","NCT07125248","Outcomes of a Single Chest Drain vs Two Drains","Outcomes of Transhiatal Drain Placement in Esophagectomy, a Randomised Control Trial","Inclusion Criteria:\n\n* All patients undergoing open esophagectomy for carcinoma of esophagus\n\nExclusion Criteria:\n\n* Non consenting individuals esophagectomy for benign disease",{"count":262,"type":21},68,[114],"Esophagectomy is a major surgical procedure done for carcinoma of esophagus. Usually bilateral chest tubes are placed in surgery for prevention of fluid accumulation in chest. However such procedure limits patients mobility and increases severity of pain. recent studies suggest that a single drain can be safe and effective. our study aims to compare the results of two chest tubes vs one.",[266,267,268],"Pleura; Effusion","Esophageal Adenocarcinoma","Esophageal Anastomotic Leak","2025-08-09",{"date":271,"type":32},"2025-08-15",{"date":273,"type":32},"2025-02-28",{"date":275,"type":21},"2025-09-10",{"name":38,"class":39},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":4,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":283,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":287,"conditions":288,"keywords":293,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":310,"locationsCount":73},"100601536","effectiveness-of-a-modified-cost-effective-dietary-plan-in-promoting-weight-loss-and-preservation-of-lean-body-mass-in-patients-after-bariatric-surgery-100601536","NCT07111767","Effectiveness of a Modified Cost-Effective Dietary Plan in Promoting Weight Loss and Preservation of Lean Body Mass in Patients After Bariatric Surgery","Inclusion Criteria:\n\n* Able to give informed written consent\n* Adults between the ages of 18 and 65 undergoing primary bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy, or OAGB)\n\nExclusion Criteria:\n\n* Patients having revision bariatric surgery\n* Patients with recognized diseases related to micronutrient supplementation\n* Patients with pre-existing gastrointestinal, metabolic, or endocrine disorders that impair nutrient absorption","65 Years",{"count":285,"type":21},122,[114],"This study will see if a low-cost dietary plan, based on the standard dietary guidelines of the American Society for Metabolic and Bariatric Surgery (ASMBS) and using locally available foods, can help patients lose weight and keep their lean body mass after bariatric surgery. It will also check if this plan can maintain healthy levels of important nutrients such as vitamin B12, iron, and vitamin D.\n\nPatients who have undergone bariatric surgery will be randomly assigned to follow either the low-cost diet or the regular hospital diet. Their weight, body composition, and nutrient levels will be tracked at baseline, and at 1, 3, and 6 months after surgery.\n\nThe aim is to find out if this simpler, affordable diet, which follows international standards, works as well as the regular plan while being easier for low-income patients to follow.",[289,290,291,292],"Obesity","Bariatric Surgery","Nutritional Status","Body Composition",[294,295,296,297,298,299,300,301,302,303],"Bariatric surgery","Obesity management","Post-bariatric diet","Cost-effective diet","Low-cost diet plan","Vitamin B12 deficiency","Iron deficiency","Vitamin D deficiency","Weight loss after bariatric surgery","Lean body mass preservation","2025-08-05",{"date":306,"type":32},"2025-08-08",{"date":308,"type":21},"2025-10",{"date":71,"type":21},{"name":38,"class":39},{"id":312,"slug":313,"hasResults":11,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":11,"sex":109,"minAge":46,"maxAge":318,"enrollmentInfo":319,"targetDuration":4,"studyType":22,"phases":320,"briefSummary":321,"conditions":322,"keywords":324,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":333,"locationsCount":334},"100591130","phase-4-comparison-of-a-face-cream-plus-a-laser-procedure-and-face-cream-alone-in-treatment-of-excessive-face-hairs-in-female-100591130","NCT06976424","Comparison of a Face Cream Plus a Laser Procedure and Face Cream Alone in Treatment of Excessive Face Hairs in Female","Comparison of Eflornithine Cream Combined With Intense Pulsed Light Versus Intense Pulsed Light Alone for Hirsutism in Women","Inclusion Criteria:\n\nGender (Female) Age between 18-45 Years Women with hirsutism as mentioned in the operational definition\n\nExclusion Criteria:\n\nPregnant women Women with severe acne Women with immunodeficiency","45 Years",{"count":285,"type":21},[50],"The study compares the effects of a cream alone and a combined effect of cream and laser for the treatment of excessive facial hairs in women .",[323],"Hirsuitism",[323,325,326],"IPL","Eflornithine","2025-07-02",{"date":329,"type":32},"2025-07-03",{"date":331,"type":21},"2025-07-15",{"date":252,"type":21},{"name":38,"class":39},3,{"id":336,"slug":337,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":342,"enrollmentInfo":343,"targetDuration":4,"studyType":22,"phases":345,"briefSummary":346,"conditions":347,"keywords":349,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":357,"leadSponsor":358,"locationsCount":73},"100591279","comparison-of-efficacy-of-microneedling-with-platelet-rich-plasma-vs-microneedling-with-topical-insulin-in-the-treatment-of-acne-scars-100591279","NCT06978361","Comparison of Efficacy of Microneedling With Platelet Rich Plasma Vs Microneedling With Topical Insulin in the Treatment of Acne Scars","Comparison of Efficacy of Microneedling With Autologous Platelet-Rich Plasma vs Microneedling With Topical Insulin in the Treatment of Atrophic Acne Scars","Inclusion Criteria:\n\nPatients confirmed with post-acne atrophic scars . No prior treatment for scars in last 6 months.\n\n\\-\n\nExclusion Criteria:\n\n* Patient with active acne or other skin conditions (e.g eczema , psoriasis). Patients on oral or topical retinoids. Pregnant or lactating Mothers. Patients with recurrent herpes simplex infection. Previous Hx of keloids \u002F hypertrophic scarring. Deranged blood glucose levels. Bleeding disorders","50 Years",{"count":344,"type":21},116,[114],"This study compares the outcome of two procedures for the treatment of atrophic acne scars.",[348],"Post-acne Atrophic Scars",[350,351,352],"Post-acne atrophic scars","Microneedling with autologous Platelet- Rich Plasma","Microneedling with topical insulin","2025-05-16",{"date":355,"type":32},"2025-05-18",{"date":226,"type":32},{"date":252,"type":21},{"name":38,"class":39},{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":367,"briefSummary":368,"conditions":369,"keywords":372,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":73},"100588327","phase-4-evaluating-the-efficacy-of-topical-insulin-for-the-restoration-of-ocular-surface-interface-in-dry-eye-disease-100588327","NCT06939959","Evaluating the Efficacy of Topical Insulin for the Restoration of Ocular Surface Interface in Dry Eye Disease.","Inclusion Criteria:\n\n* Patients having Schirmer's test values of less than 10mm after 5 minutes of the procedure recording plus a non-invasive tear breakup time (TBUT) of less than 10 seconds and the Ocular Surface Disease Index (OSDI) of more than 32 (diagnosed as dry eye disease as per the operational definition of this study).\n* any gender.\n* aged 18 years and above.\n\nExclusion Criteria:\n\n* Patients with active ocular infection, severe ocular surface disease other than Dry eye disease, and those who have undergone ocular surgery within the past 6 months.\n* Under 18 years old",{"count":366,"type":21},126,[50],"This is a parallel randomized controlled trial for the treatment of dry eye disease. The main objective is to investigate the efficacy and safety of the use of insulin eye drops in the control of moderate-severe dry eye disease. Topical insulin drops will be compared to artificial tears in improving the ocular surface interface in patients with dry eye disease over 1 year period.",[370,371],"Dry Eye","Insulin Sensitivity",[373,374,375],"DRY EYE DISEASE","Topical Insulin","Ocular Surface Interface restoration","2025-04-15",{"date":378,"type":32},"2025-04-23",{"date":380,"type":32},"2025-04-14",{"date":382,"type":21},"2026-04-20",{"name":38,"class":39},{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":342,"enrollmentInfo":390,"targetDuration":4,"studyType":22,"phases":392,"briefSummary":393,"conditions":394,"keywords":396,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":403,"leadSponsor":404,"locationsCount":73},"100586973","phase-4-comparison-of-efficacy-of-oral-fluconazole-versus-oral-itraconazole-in-the-treatment-of-pityriasis-versicolor-100586973","NCT06922344","Comparison of Efficacy of Oral Fluconazole Versus Oral Itraconazole in the Treatment of Pityriasis Versicolor","Inclusion Criteria:\n\n* All cases of Pityriasis versicolor\n\nExclusion Criteria:\n\n* Patients with history of chronic renal or liver disease, malignancy , or undergoing any kind of chemotherapy or radiotherapy or having cardiac conduction abnormalities.\n* Patients who received any anti-fungal therapy in the last one month.\n* Pregnant or lactating women.",{"count":391,"type":21},106,[50],"This study compares the efficacy of two drugs, namely flucanazole and itraconazole for the treatment of a common fungal infection of skin.",[395],"Pityriasis Versicolor",[395,397,398],"Fluconazole","Itraconazole","2025-04-09",{"date":401,"type":32},"2025-04-10",{"date":226,"type":32},{"date":252,"type":21},{"name":38,"class":39},{"id":406,"slug":407,"hasResults":11,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":16,"minAge":210,"maxAge":283,"enrollmentInfo":412,"targetDuration":4,"studyType":22,"phases":414,"briefSummary":415,"conditions":416,"keywords":422,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":73},"100585739","resumption-of-enteral-feeding-after-bowel-anastomosis-100585739","NCT06906289","Resumption of Enteral Feeding After Bowel Anastomosis","Comparison of Early Versus Late Resumption of Enteral Feeding After Small Bowel Anastomosis.","Inclusion Criteria:\n\n* All patients undergoing small bowel anastomosis for any indication in elective setting\n* Patients of age between 15 to 65 years.\n* All genders\n\nExclusion Criteria:\n\n* Patient using glucocorticoids or other immunosuppressive drugs\n* non conseting individuals\n* Patient having history of gastrectomy",{"count":413,"type":21},204,[114],"Resumption of oral feeding after small intestine surgery is a matter of controversy .Some surgeons advocate early resumption while others don't.early feeding is initiated as soon as the patient recovers from effects of anaesthesia, while late resumption is started after 24-48 hours after surgery.Recent studies and guidelines suggest early feeding. The aim of this study is to compare the early and late resumption of oral feeding.",[417,418,419,194,420,421],"Enhanced Recovery After Surgery","Hospital Stay, Length of Stay in Hospital From Time of Surgery Till Discharge","Defecation","Anastomotic Leak","Flatus",[423,424,425,426],"Enhanced Recover After Surgery","Hospital Stay","Postoperative vomiting","Anastomotic leak","2025-03-25",{"date":429,"type":32},"2025-04-02",{"date":431,"type":32},"2024-10-01",{"date":433,"type":21},"2025-12",{"name":38,"class":39},""]